• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.在体外竞争性HIV-1复制试验中多双脱氧核苷抗性1型人类免疫缺陷病毒(HIV-1)的相对适应性
J Virol. 1999 Jul;73(7):5356-63. doi: 10.1128/JVI.73.7.5356-5363.1999.
2
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.具有赋予多双脱氧核苷抗性的 pol 基因突变的 1 型人类免疫缺陷病毒的药物敏感性改变、适应性及进化。
J Infect Dis. 1998 May;177(5):1207-13. doi: 10.1086/515282.
3
Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants.多双脱氧核苷抗性HIV-1变体出现的途径。
AIDS. 2003 May 23;17(8):1127-37. doi: 10.1097/00002030-200305230-00003.
4
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.人类免疫缺陷病毒1型通过同源重组获得对两类抗病毒药物的耐药性。
Antiviral Res. 1997 Dec;36(3):179-89. doi: 10.1016/s0166-3542(97)00053-3.
5
The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.HIV-1 逆转录酶 A62V 突变影响多药耐药突变背景下的复制保真度和病毒适应性。
Viruses. 2018 Jul 19;10(7):376. doi: 10.3390/v10070376.
6
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.齐多夫定耐药的1型人类免疫缺陷病毒分离株在体外的相对复制适应性
J Virol. 1998 May;72(5):3773-8. doi: 10.1128/JVI.72.5.3773-3778.1998.
7
Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.携带D67N或K219Q/E突变的1型人类免疫缺陷病毒在体外迅速演变为对齐多夫定耐药,并且在有齐多夫定存在的情况下显示出高复制适应性。
J Virol. 2004 Jul;78(14):7545-52. doi: 10.1128/JVI.78.14.7545-7552.2004.
8
Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.对赋予多核苷类药物抗性的HIV逆转录酶突变Q151M及其复合物的结构洞察
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00224-17. Print 2017 Jun.
9
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.从不同欧洲国家患者中分离出的多重双脱氧核苷类似物耐药(MddNR)HIV-1毒株。
AIDS. 1998 Oct 22;12(15):2007-15. doi: 10.1097/00002030-199815000-00012.
10
The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity.1型人类免疫缺陷病毒逆转录酶中多脱氧核苷抗性赋予突变对聚合酶保真度和错误特异性的影响。
J Virol. 1998 Apr;72(4):2890-5. doi: 10.1128/JVI.72.4.2890-2895.1998.

引用本文的文献

1
Structural and virologic mechanism of the emergence of resistance to M inhibitors in SARS-CoV-2.SARS-CoV-2 中对 M 抑制剂耐药性产生的结构和病毒学机制。
Proc Natl Acad Sci U S A. 2024 Sep 10;121(37):e2404175121. doi: 10.1073/pnas.2404175121. Epub 2024 Sep 5.
2
The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.HIV-1 逆转录酶 A62V 突变影响多药耐药突变背景下的复制保真度和病毒适应性。
Viruses. 2018 Jul 19;10(7):376. doi: 10.3390/v10070376.
3
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.达芦那韦(DRV)对 HIV-1 耐药性具有高遗传屏障的机制:蛋白酶中的一个关键 V32I 取代很少发生,但一旦发生,就会使 HIV-1 易于产生对 DRV 的耐药性。
mBio. 2018 Mar 6;9(2):e02425-17. doi: 10.1128/mBio.02425-17.
4
Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.HIV-2 逆转录酶中的 V111I 突变增加了核苷类似物耐药的 K65R 和 Q151M 病毒的适应性。
J Virol. 2015 Jan;89(1):833-43. doi: 10.1128/JVI.02259-14. Epub 2014 Oct 29.
5
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.HIV-1 逆转录酶与抗病毒药物耐药性。第 2 部分。
Curr Opin Virol. 2013 Apr;3(2):119-28. doi: 10.1016/j.coviro.2013.03.014. Epub 2013 Apr 19.
6
Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.S138A 取代恩夫韦肽的耐药机制及其在肽设计中的应用。
Int J Biochem Cell Biol. 2013 Apr;45(4):908-15. doi: 10.1016/j.biocel.2013.01.015. Epub 2013 Jan 26.
7
Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.免疫逃逸突变对同源传播/原始基因组中 HIV-1 适应性的影响。
Retrovirology. 2012 Oct 30;9:89. doi: 10.1186/1742-4690-9-89.
8
HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate.具有新型作用机制的 HIV-1 RT 抑制剂:与核苷酸底物竞争的 NNRTIs。
Viruses. 2010 Apr;2(4):880-899. doi: 10.3390/v2040880. Epub 2010 Mar 30.
9
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.HIV-1 逆转录酶向获得 Q151M 多药耐药性的进化是复杂的,涉及多个结构域的突变。
Retrovirology. 2011 May 11;8:31. doi: 10.1186/1742-4690-8-31.
10
Mechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase.HIV-1 逆转录酶 Q151L 突变导致对 GS-9148 产生耐药性的机制。
Antimicrob Agents Chemother. 2011 Jun;55(6):2662-9. doi: 10.1128/AAC.01738-10. Epub 2011 Mar 14.

本文引用的文献

1
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.西班牙初治和经治的HIV感染患者中对核苷类似物基因型耐药的流行情况。
AIDS. 1998 Jun 18;12(9):1015-20.
2
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
J Infect Dis. 1998 Jun;177(6):1506-13. doi: 10.1086/515324.
3
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.具有赋予多双脱氧核苷抗性的 pol 基因突变的 1 型人类免疫缺陷病毒的药物敏感性改变、适应性及进化。
J Infect Dis. 1998 May;177(5):1207-13. doi: 10.1086/515282.
4
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.齐多夫定耐药的1型人类免疫缺陷病毒分离株在体外的相对复制适应性
J Virol. 1998 May;72(5):3773-8. doi: 10.1128/JVI.72.5.3773-3778.1998.
5
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.人类免疫缺陷病毒1型通过同源重组获得对两类抗病毒药物的耐药性。
Antiviral Res. 1997 Dec;36(3):179-89. doi: 10.1016/s0166-3542(97)00053-3.
6
Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay.使用单核苷酸掺入试验对耐2',3'-双脱氧核苷酸类似物的HIV-1逆转录酶进行的比较酶学研究。
Biochemistry. 1997 Feb 4;36(5):1092-9. doi: 10.1021/bi962393d.
7
Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.一株高效复制的1型人类免疫缺陷病毒患者毒株对核苷类似物和非核苷逆转录酶抑制剂的多重耐药性
J Infect Dis. 1996 Nov;174(5):962-8. doi: 10.1093/infdis/174.5.962.
8
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.人类免疫缺陷病毒1型逆转录酶210位氨基酸变异对齐多夫定敏感性的意义
J Virol. 1996 Sep;70(9):5930-4. doi: 10.1128/JVI.70.9.5930-5934.1996.
9
Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.在选择性药物压力下,重组导致HIV-1双重耐药突变体迅速出现。
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6106-11. doi: 10.1073/pnas.93.12.6106.
10
Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.齐多夫定筛选出的人类免疫缺陷病毒1型逆转录酶氨基酸取代对持续性DNA合成和病毒复制的影响。
J Virol. 1996 Apr;70(4):2146-53. doi: 10.1128/JVI.70.4.2146-2153.1996.

在体外竞争性HIV-1复制试验中多双脱氧核苷抗性1型人类免疫缺陷病毒(HIV-1)的相对适应性

Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.

作者信息

Kosalaraksa P, Kavlick M F, Maroun V, Le R, Mitsuya H

机构信息

Experimental Retrovirology Section, Department of Developmental Therapeutics, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

J Virol. 1999 Jul;73(7):5356-63. doi: 10.1128/JVI.73.7.5356-5363.1999.

DOI:10.1128/JVI.73.7.5356-5363.1999
PMID:10364282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC112591/
Abstract

We examined whether human immunodeficiency virus type 1 (HIV-1) fitness was altered upon the acquisition of a set or subset of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene, which confers resistance to multiple dideoxynucleosides (MDR), as well as the zidovudine resistance-associated mutation T215Y, using a competitive HIV-1 replication assay in a setting of an HXB2D genetic background. Target H9 cells were exposed to a 50:50 mixture of paired infectious molecular clones, and HIV-1 in the culture supernatant was transmitted to new cultures every 7 to 10 days. The polymerase-encoding region of the virus was sequenced at various time points, and the relative proportion of the two viral populations was determined. In the absence of drugs, the comparative order for replicative fitness was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-1151 > wild-type HIV-1 (HIV-1wt) > HIV-175/77/116/151 > HIV-1151/215 > HIV-1215. In the presence of zidovudine or didanosine, the order was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-175/77/116/151 > HIV-1151 > HIV-1215. HIV-1215S(TCC), a putative intermediate infectious clone for HIV-1215, replicated comparably to HIV-1wt, while two putative intermediates for HIV-1151 [HIV-1151L(CTG) and HIV-1151K(AAG)] replicated much less efficiently than HIV-1wt and HIV-1151, suggesting that for HIV-1151 to develop, two base substitutions are likely to occur concurrently or within a short interval. These data may illustrate the molecular basis by which HIV-1151 emerges much less frequently than HIV-1215. The present data also demonstrate that several MDR HIV-1 variants are more fit than HIV-1wt in the absence of drugs and that resistance-associated mutations and drug pressure are critical variates for HIV-1 fitness.

摘要

我们使用竞争性HIV-1复制试验,在HXB2D遗传背景下,研究了1型人类免疫缺陷病毒(HIV-1)在获得pol基因中的一组或一个子集的五个突变(A62V、V75I、F77L、F116Y和Q151M)后其适应性是否发生改变,这些突变赋予了对多种双脱氧核苷(MDR)的抗性以及齐多夫定抗性相关突变T215Y。将靶细胞H9暴露于成对感染性分子克隆的50:50混合物中,并且每7至10天将培养上清液中的HIV-1传播至新的培养物中。在不同时间点对病毒的聚合酶编码区进行测序,并确定两个病毒群体的相对比例。在无药物情况下,复制适应性的比较顺序为:HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-1151 > 野生型HIV-1(HIV-1wt)> HIV-175/77/116/151 > HIV-1151/215 > HIV-1215。HIV-1215S(TCC)是HIV-1215的一个假定中间感染性克隆,其复制效率与HIV-1wt相当,而HIV-1151的两个假定中间体[HIV-1151L(CTG)和HIV-11五万一千(AAG)]的复制效率远低于HIV-1wt和HIV-1151,表明对于HIV-1151的产生,两个碱基替换可能同时发生或在短时间间隔内发生。这些数据可能说明了HIV-1151出现频率远低于HIV-1215的分子基础。目前的数据还表明,几种MDR HIV-1变体在无药物情况下比HIV-1wt更具适应性,并且抗性相关突变和药物压力是HIV-1适应性的关键变量。